Home  |  Contact

Cellosaurus PEO14 (CVCL_2687)

[Text version]

Cell line name PEO14
Synonyms PE014; PEO-14
Accession CVCL_2687
Resource Identification Initiative To cite this cell line use: PEO14 (RRID:CVCL_2687)
Comments Part of: MD Anderson Cell Lines Project.
Part of: OCCP ovarian cancer cell line panel.
Doubling time: 108 hours (PubMed=3167863).
Omics: Deep RNAseq analysis.
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Sequence variations Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Unspecified (PubMed=25230021; PubMed=28273451).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*11:01,11:01
HLA-BB*35:01,35:01
HLA-CC*04:01,04:01
Class II
HLA-DQDQB1*05:01,05:01
HLA-DRDRB1*01:03,01:03
Disease Ovarian cystadenocarcinoma (NCIt: C5228)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_2689 ! PEO23
CVCL_2734 ! TO14
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): ECACC; PubMed=25230021; PubMed=30485824

Markers:
AmelogeninX
CSF1PO11
D2S133819
D3S135816,18
D5S81811,12 (ECACC)
12 (PubMed=25230021; PubMed=30485824)
D7S8209,10
D8S117913,14
D13S31711,12
D16S53911
D18S5115
D19S43314,15
D21S1127,30
FGA20
Penta D9,13
Penta E10
TH016
TPOX8,11
vWA15,16

Run an STR similarity search on this cell line
Web pages https://tcpaportal.org/mclp/
Publications

PubMed=3167863
Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A., Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Cancer Res. 48:6166-6172(1988)

PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-#
Mullen P., Ritchie A., Langdon S.P., Miller W.R.
Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.
Int. J. Cancer 67:816-820(1996)

PubMed=20581869; DOI=10.1038/onc.2010.245
Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T., Temple J., Langdon S.P., Huntsman D.G., Brenton J.D.
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
Oncogene 29:4905-4913(2010)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=25230021; DOI=10.1371/journal.pone.0103988
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P., Novak M., Doodnauth S.A., Saiz F.S., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R., Ailles L., Mes-Masson A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

Cross-references
Cell line collections ECACC; 10032311
Ximbio; 151675
Cell line databases/resources Cell_Model_Passport; SIDM01419
Ontologies EFO; EFO_0005446
Gene expression databases GEO; GSM313700
GEO; GSM459856
GEO; GSM659402
GEO; GSM2474998
Other Wikidata; Q54947165
Polymorphism and mutation databases Cosmic; 1305318
Progenetix; CVCL_2687
Entry history
Entry creation04-Apr-2012
Last entry update20-May-2021
Version number19